Document is current
Any future updates will be listed below
-
Authors
Arroyo-Araujo, María
Graf, Radka
Maco, Martine
van Dam, Elsbeth
Schenker, Esther
Drinkenburg, Wilhelmus
Koopmans, Bastijn
de Boer, Sietse F.
Cullum-Doyle, Michaela
Noldus, Lucas P. J. J.
Loos, Maarten https://orcid.org/0000-0003-1629-2928
van Dommelen, Wil
Spooren, Will
Biemans, Barbara
Buhl, Derek L.
Kas, Martien J. https://orcid.org/0000-0002-4471-8618
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115300, 115300, 115300, 115300, 115300, 115300, 115300, 115300, 115300)
- License Information
-
More Information
Article History
Received: 26 April 2019
Accepted: 25 July 2019
First Online: 12 August 2019
Competing Interests
: During the study, R.G., M.C-D., and D.L.B. were full time employees and shareholders of Pfizer, Inc. D.L.B. is currently a fully time employee and shareholder of Takeda Pharmaceutical Company, Ltd. M.M., W.S. and B.B. are fully employed by Roche. E.v.D., W.v.D., and L.P.J.J.N. are fully employed by Noldus Information Technology. E.S. is full time employee of Servier. W.D. is fully employed by Janssen Pharmaceutica NV and holds stocks and options. B.K. and M.L. are fully employed by Sylics. L.N. is the majority shareholder of Noldus Information Technology BV.
